Sacituzumab govitecan: tested in a combination
46 studies: another drug in the study is under test too. Page 1 of 1. Open to participants first (30), then studies with results posted, then the rest; newest registration first within each.
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingNCT07825753Phase 2Report a problem
- IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian CancerNot yet recruitingNCT07674615Phase 1Report a problem
- Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell CarcinomaRecruitingNCT07492914Phase 2Report a problem
- Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingNCT07393555Phase 2Report a problem
- Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast CancerNot yet recruitingNCT07368543Phase 2Report a problem
- Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBCEnrolling by invitationNCT07359404Phase 2Report a problem
- Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerRecruitingNCT07339059Phase 2Report a problem
- TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast CancerNot yet recruitingNCT07271992Phase 2Report a problem
- A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 InhibitorsNot yet recruitingNCT07163481Phase 1Report a problem
- A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)RecruitingNCT07063212Phase 2Report a problem
- Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)RecruitingNCT07011654Phase 1/2Report a problem
- A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast CancerRecruitingNCT06878625Phase 2Report a problem
- Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerRecruitingNCT06801834Phase 3Report a problem
- Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionRecruitingNCT06739395Phase 2Report a problem
- Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk RecurrenceRecruitingNCT06682728Phase 2Report a problem
- First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+TrodelvyRecruitingNCT06667167Phase 2Report a problem
- Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder CancerNot yet recruitingNCT06528483Phase 2Report a problem
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerRecruitingNCT06524544Phase 3Report a problem
- Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.RecruitingNCT06431633Phase 3Report a problem
- Sequential Therapies Modeled on Evolutionary Dynamics for Breast CancerRecruitingNCT06409390Phase 2Report a problem
- Investigator Grant (IG) 2022 27746RecruitingNCT06341478Not applicableReport a problem
- Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)RecruitingNCT06311214Phase 2Report a problem
- Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...RecruitingNCT06161532Phase 2Report a problem
- Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard TherapyRecruitingNCT06065371Phase 1Report a problem
- Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial CancerRecruitingNCT06040970Phase 1/2Report a problem
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerRecruitingNCT05601440Phase 2Report a problem
- Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)RecruitingNCT05332561Phase 2Report a problem
- Sacituzumab Govitecan Plus EV in Metastatic UCRecruitingNCT04724018Phase 1/2Report a problem
- Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)RecruitingNCT04434040Phase 2Report a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingNCT03424005Phase 1/2Report a problem
- A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)Active, not recruitingNCT05327530Phase 2Results postedReport a problem
- A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)TerminatedNCT03992131Phase 1/2Results postedReport a problem
- Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)TerminatedNCT03869190Phase 1/2Results postedReport a problem
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedNCT03337698Phase 1/2Results postedReport a problem
- Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine CancerWithdrawnNCT07328490Phase 1/2Report a problem
- PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder CancerActive, not recruitingNCT06133517Phase 2Report a problem
- A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)Active, not recruitingNCT06100874Phase 2Report a problem
- Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung CancerActive, not recruitingNCT06055465Phase 2Report a problem
- A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)Active, not recruitingNCT05675579Phase 2Report a problem
- Study of Novel Treatment Combinations in Patients With Lung CancerActive, not recruitingNCT05633667Phase 2Report a problem
- Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder CancerActive, not recruitingNCT05535218Phase 2Report a problem
- Alpelisib And Sacituzumab Govitecan For Treatment Of Breast CancerActive, not recruitingNCT05143229Phase 1Report a problem
- StrataPATH™ (Precision Indications for Approved Therapies)TerminatedNCT05097599Phase 2Report a problem
- Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma PatientsActive, not recruitingNCT04863885Phase 1/2Report a problem
- Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast CancerActive, not recruitingNCT03971409Phase 2Report a problem
- Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadActive, not recruitingNCT03547973Phase 2Report a problem